Skip to main content
. Author manuscript; available in PMC: 2022 Apr 10.
Published in final edited form as: Sci Transl Med. 2021 Jan 20;13(577):eaba7401. doi: 10.1126/scitranslmed.aba7401

Figure 2. CHK1/2 inhibitors synergize with DNA-damaging chemotherapies in MB cells.

Figure 2.

(A) Dose-response analyses of the indicated CHK1/2 or CHK1 inhibitors in D283 (red) and D425 (blue) cells. The ED50 is indicated. Mean ± SEM were calculated from 3–4 independent experiments. (B) Results from assays to determine the interactions between the four CHK inhibitors shown and three MB chemotherapies: 4-HPC, CDDP, and GEM. The mean combination index (CI, horizontal bar) was determined from the indicated pairwise drug combinations using D283 and D425 cells, with 3–5 independent experiments performed. Result for each experiment is indicated by the symbols. Table provides the summary of data shown in B (mean CI ± SD). Synergistic interactions are in green; additive interactions are indicated in black.